Search

Your search keyword '"Vinolas N"' showing total 110 results
Start Over Author "Vinolas N"
110 results on '"Vinolas N"'

1. Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types

Author

Paré, L., Pascual, T., Seguí, E., Teixidó, C., Gonzalez-Cao, M., Galván, P., Rodríguez, A., González, B., Cuatrecasas, M., Pineda, E., Torné, A., Crespo, G., Martin-Algarra, S., Pérez-Ruiz, E., Reig, Ò, Viladot, M., Font, C., Adamo, B., Vidal, M., Gaba, L., Muñoz, M., Victoria, I., Ruiz, G., Viñolas, N., Mellado, B., Maurel, J., Garcia-Corbacho, J., Molina-Vila, M Á, Juan, M., Llovet, J.M., Reguart, N., Arance, A., and Prat, A.

Published
2018
Full Text
View/download PDF

2. OA13.04 Prevalence of Molecular Alterations in NSCLC and Estimated Indoor Radon in Europe: RADON EUROPE Study

Author

Garcia, M., primary, Garcia de Herreros, M., additional, Auclin, E., additional, Caravaca, G., additional, Sart, J., additional, Riudavets, M., additional, Vasseur, D., additional, Albarran-Artahona, V., additional, Laguna, J.C., additional, Gorria, T., additional, Castro, R. Lopez, additional, Teixido, C., additional, Castellano, G., additional, Martinez, A. Bedmar, additional, Arcocha, A., additional, Vinolas, N., additional, Reyes, R., additional, Prat, A., additional, Reguart, N., additional, Elio, J., additional, Leighl, N., additional, Besse, B., additional, and Mezquita, L., additional

Published
2022
Full Text
View/download PDF

3. Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies

Author

Moran, T., Wei, J., Cobo, M., Qian, X., Domine, M., Zou, Z., Bover, I., Wang, L., Provencio, M., Yu, L., Chaib, I., You, C., Massuti, B., Song, Y., Vergnenegre, A., Lu, H., Lopez-Vivanco, G., Hu, W., Robinet, G., Yan, J., Insa, A., Xu, X., Majem, M., Chen, X., de las Peñas, R., Karachaliou, N., Sala, M.A., Wu, Q., Isla, D., Zhou, Y., Baize, N., Zhang, F., Garde, J., Germonpre, P., Rauh, S., ALHusaini, H., Sanchez-Ronco, M., Drozdowskyj, A., Sanchez, J.J., Camps, C., Liu, B., Rosell, R., Colinet, B., De Grève, J., Germonpré, P., Chen, H., Du, J., Gao, Y., Hu, J., Kong, W., Li, L., Li, R., Li, X., Liu, J., Ren, W., Wen, L., Xiao, X., Yang, J., Yang, M., Yang, Y., Yin, J., Yue, X., Zhang, J., Zhu, L., Bombaron, P., Chouaid, C., Dansin, E., Fournel, P., Fraboulet, G., Gervais, R., Hominal, S., Kahlout, S., Lecaer, H., Lena, H., LeTreut, J., Locher, C., Molinier, O., Monnet, I., Oliviero, G., Schoot, R., Thomas, P., Vergnènegre, A., Berchem, G., Al Husaini, H., Aparisi, F., Arriola, E., Ballesteros, I., Barneto, I., Bernabé, R., Blasco, A., Bosch-Barrera, J., Calvo de Juan, V., Carcereny, E., Catot, S., De las Peñas, R., Dómine, M., Felip, E., García-Campelo, M.R., García-Girón, C., García-Gómez, R., Garcia-Sevila, R., Gasco, A., Gil, J., González-Larriba, J.L., Hernando-Polo, S., Jantus, E., Jiménez, B., Lianes, P., López-López, R., López-Martín, A., López-Vivanco, G., Macias, J.A., Marti-Ciriquian, J.L., Montoyo, R., Morales-Espinosa, D., Morán, T., Moreno, M.A., Pallares, C., Parera, M., Pérez-Carrión, R., Porta, R., Reguart, N., Rosillo, F., Sanchez, J.M., Sullivan, I., Terrasa, J., Trigo, J.M., Valdivia, J., Viñolas, N., Viteri, S., Botia-Castillo, M., Mate, J.L., Perez-Cano, M., Ramirez, J.L., Sanchez-Rodriguez, B., Taron, M., Tierno-Garcia, M., Mijangos, E., Ocaña, J., Pereira, E., Shao, J., Sun, X., and O'Brate, R.

Published
2014
Full Text
View/download PDF

5. Pre-treatment tissue TCR repertoire evenness is associated with complete pathological response in patients with NSCLC receiving neoadjuvant chemoimmunotherapy

Author

Casarrubios M, Cruz-Bermudez A, Nadal E, Insa A, Garcia-Campelo R, Lazaro M, Domine M, Majem M, Rodriguez-Abreu D, Martinez-Marti A, de Castro-Carpeno J, Cobo M, Lopez-Vivanco G, Del Barco E, Bernabe Caro R, Vinolas N, Barneto Aranda I, Viteri S, Massuti B, Barquin M, Laza-Briviesca R, Sierra-Rodero B, Parra E, Sanchez-Espiridion B, Rocha P, Kadara H, Wistuba I, Romero A, Calvo V, and Provencio M

Abstract

PURPOSE: Characterization of the T-cell receptor (TCR) repertoire may be a promising source for predictive biomarkers of pathological response to immunotherapy in locally-advanced non-small cell lung cancer (NSCLC). EXPERIMENTAL DESIGN: In this study, next-generation TCR sequencing was performed in peripheral blood and tissue samples of 40 NSCLC patients, before and after neoadjuvant chemoimmunotherapy (NADIM clinical trial, NCT03081689), considering their complete pathologic response (CPR) or non-CPR. Beyond TCR metrics, tissue clones were ranked by their frequency and spatiotemporal evolution of top 1% clones was determined. RESULTS: We have found a positive association between an uneven TCR repertoire in tissue samples at diagnosis and CPR at surgery. Moreover, TCR most frequent-ranked clones (top 1%) present in diagnostic biopsies occupied greater frequency in the total clonal space of CPR patients, achieving an AUC ROC to identify CPR patients of 0.967 (95% CI, 0.897 to 1.000; p=0.001), and improving the results of PD-L1 TPS (AUC 0.767; p=0.026) or TMB (AUC 0.550; p=0.687). Furthermore, tumors with high pre-treatment top 1% clonal space showed similar immune cell populations but a higher immune reactive gene expression profile. Finally, the selective expansion of pre-treatment tissue top 1% clones in peripheral blood of CPR patients suggests also a peripheral immunosurveillance, which could explain the high survival rate of these patients. CONCLUSIONS: We have identified two parameters derived from TCR repertoire analysis that could outperform PD-L1 TPS and TMB as predictive biomarkers of CPR after neoadjuvant chemoimmunotherapy, and unraveled possible mechanisms of CPR involving enhanced tumor immunogenicity and peripheral immunosurveillance.

Published
2021

6. A multicenter phase I study of radium-223 (Ra-223) plus pembrolizumab in patients with stage IV non-small cell lung cancer (NSCLC)

Author

Reck, M., Mileham, K., Paz-Ares, L., Surmont, V., Felip, E., Vinolas, N., Bessudo, A., Clump, D., Decoster, L., Estival, A., Sebastian, M., Chen, H., Chisamore, M., Wagner, V. J., Wagner, A., Smit, E. F. F., Clinical sciences, Medical Oncology, and Laboratory of Molecular and Medical Oncology

Abstract

Background: Nivolumab or pembrolizumab is the standard second-line treatment for patients (pts) with advanced NSCLC. Anlotinib is an oral VEGFR, FGFR, PDGFR and c-Kit tyrosine kinase inhibitor. The interaction between tumor immune microenvironment and angiogenesis has been well established.This study was designed to assess the benefit and optimal time of nivolumab or pembrolizumab plus anlotinib in previously treated advanced NSCLC. Methods: This is a prospective observational study. Pts with advanced NSCLC who had previous progression after platinum-based chemotherapy were eligible. For NSCLC with EGFR variations pts who had disease progression with prior EGFR TKI therapies and chemotherapy were also eligible. Nivolumab on day 1 (3 mg/kg) every 2 weeks or pembrolizumab on day 1 (200 mg) every 3 weeks for up to 8 weeks, for pts who have no symptomatic deterioration and can benefit from the treatment, then followed by the former therapy plus anlotinib maintenance until progression or unacceptable toxic effects. Anlotinib was given orally 12mg for 2 weeks of a 21-day cycle (days 1-14). The primary outcome was ORR. The secondary outcomes were DCR, PFS, OS and safety. Results: From Mar-2019 to Apr-2021, a total of 19 pts were enrolled. Most were male (84.2%), adenocarcinoma histology (68.4%) and most were treated as second-line treatment (57.9%). 4 had baseline brain metastases. For 8 weeks’ treatment of nivolumab or pembrolizumab monotherapy, 5 pts achieved PR, 8 pts achieved SD and 6 pts had PD; ORR was 26.3%, DCR was 73.7%. During the anti-PD-1 therapy plus anlotinib, 1 pt achieved CR, 12 pts achieved PR (4 of them were PD during monotherapy), 4 pts achieved SD. ORR was 68.4%, DCR was 89.5%. Median PFS was 13.1 months (95% CI 8.6 to14.9). Grade 3 TRAE occurred in 26% pts. 2 pts with squamous cell carcinoma died due to pulmonary embolism and respiratory tract hemorrhage. The most common TRAE were fatigue, hypothyroidism and rash. Conclusions: Anti-PD-1 therapy plus anlotinib has shown promising anti-tumor efficacy compared to the previous anti-PD-1 monotherapy studies for pts with previously treated advanced NSCLC, and with a tolerable safety profile. We may focus on exploring the optimal time and advantage group of this combination in future studies.

Published
2021

7. Clinical Activity of Afatinib in Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Spanish Retrospective Multicenter Study

Author

Moran, T, Taus, A, Arriola, E, Aguado, C, Domine, M, Rueda, AG, Calles, A, Cedres, S, Vinolas, N, Isla, D, Palmero, R, Sereno, M, Diaz, V, Juan, O, Marse, R, Martorell, PM, and Torres, JMS

Subjects
Retrospective, Afatinib, NSCLC, Uncommon, EGFR mutations
Abstract

We report the results of the molecular and clinical characterization and the efficacy of afatinib in a cohort of patients with advanced nonesmall-cell lung cancer (NSCLC) patients harboring uncommon epidermal growth factor receptor (EGFR) mutations in Spanish clinical practice. In patients with uncommon EGFR-mutant NSCLC, the most common mutations occurred on exon 18 in amino acid G719, either alone or in combination with another mutation; other uncommon mutations were detected in exons 18, 19, 20, 21, and 22. In clinical practice, afatinib was active in patients with uncommon EGFR-mutant NSCLC, particularly in patients with complex and single mutations; however, in patients with EGFR ins20 (EGFR exon 20 insertions), treatment with afatinib provided a lower clinical benefit, indicating that further treatment strategies are needed for patients with this type of uncommon EGFR mutation. Introduction: Uncommon epidermal growth factor receptor (EGFR) mutations (u-EGFRm) are a heterogeneous group of molecular alterations and have also been reported as comutations with other EGFR mutations (complex mutations) in nonesmall-cell lung cancer (NSCLC). Afatinib has shown activity against some u-EGFRm, and we examined its efficacy in Spanish clinical practice. Patients and Methods: Data of 67 patients with advanced NSCLC with u-EGFRm treated with afatinib between 2012 and 2017 at 23 Spanish institutions were reviewed. u-EGFRm were analyzed as complex mutations (group A), EGFR exon 20 insertions (ins20; group B), or single mutations (group C). Efficacy was evaluated in terms of overall survival (OS) and tumor response. Results: Group A complex u-EGFRm consisted of double mutations of G719X+E709F, G719X+S768I, G719X+L861Q, L858R+T790M, L858R+S768I, L858R+S765I, del19+S768I, del19+L747S, or R776C+L861Q. No differences in clinical characteristics were found between groups A (n= 20), B (n= 23), and C (n= 24). Afatinib was administered as first-line therapy in 80% of patients. Median time of receipt of therapy was 4.2 months (range, 2.0-12.9 months). Median OS for the entire cohort was 19.9 months (95% confidence interval, 9.7, 30.1). Hazard ratios for OS were 0.26 (95% confidence interval, 0.10, 0.71; P=.008) and 0.40 (95% confidence interval, 0.17, 0.95; P=.037) for groups A and C compared to B, respectively. Response was significantly higher in groups A (70%) and C (54%) compared to B (13%; pairwise comparison P

Published
2020

14. OA20.02 Pre-Treatment Levels of ctDNA for Long-Term Survival Prediction in Stage IIIA NSCLC Treated With Neoadjuvant Chemo-Immunotherapy

Author

Romero, A., Nadal, E., Serna, R., Insa, A., Campelo, M.R. García, Benito, C., Domine, M., Majem, M., Abreu, D. Rodriguez, Martinez-Marti, A., De Castro, J., Cobo, M., Vivanco, G. López, Del Barco, E., Bernabé, R., Viñolas, N., Barneto, I., Viteri, S., Pereira, E., Royuela, A., Casarrubios, M., Calvo, V., Laza - Briviesca, R., Massuti, B., Cruz, A., Sánchez-Herrero, E., and Provencio, M.

Published
2021
Full Text
View/download PDF

15. OA20.01 Long Term Survival in Operable Stage Iiia Nsclc Patients Treated With Neoadjuvant Nivolumab Plus Chemotherapy - Nadim Study

Author

Provencio, M., Nadal, E., Insa, A., Campelo, M.R. García, Pereiro, D., Domine, M., Majem, M., Abreu, D. Rodriguez, Martinez-Marti, A., De Castro, J., Cobo, M., Vivanco, G. López, Del Barco, E., Bernabé, R., Viñolas, N., Barneto, I., Viteri, S., Pereira, E., Royuela, A., Casarrubios, M., Salas, C., Parra, E.R., Wistuba, I., Calvo, V., Laza - Briviesca, R., Romero, A., Massuti, B., and Cruz, A.

Published
2021
Full Text
View/download PDF

20. 92P First-results of the CLIMB360 study, a prospective molecular screening program across multiple cancer types based on circulating tumor DNA (ctDNA)

Author

Garcia-Corbacho, J., Victoria Ruiz, I., Angelats, L., Indacochea, A., Martínez-Vidal, J., Sole Bentz, P., Moreno, D., Faull, I., Campillo, M.L., Muñoz, S., Saurí, T., Reguart Aransay, N., Viñolas, N., Esposito, F.M., Mezquita, L., Basté, N., Oliveres, H., Castillo, S., Nogué, M., and Prat, A.

Published
2021
Full Text
View/download PDF

21. 81P Baseline circulating CD4+PD1+high T cells (TCD4PD1H) as predictors of survival in patients (P) with solid tumors treated with immune-checkpoint inhibitors (ICI)

Author

Garcia-Corbacho, J., Navarro, A.E. González, Victoria, I., Moreno, D., Heredia, L., Ortiz de Landázuri, I., Díez-Guardia, V., Sanfeliu, E., Indacochea, A., Angelats, L., Viñolas, N., Mellado, B., Saurí, T., Maurel, J., Mezquita, L., Pineda, E., Basté, N., Prat, A., Juan, M., and Schettini, F.

Published
2021
Full Text
View/download PDF

22. A consensus statement on the gender perspective in lung cancer

Author

Isla, D, Majem, M, Vinolas, N, Artal, A, Blasco, A, Felip, E, Garrido, P, Remon, J, Baquedano, M, Borras, JM, Die Trill, M., Garcia-Campelo, R, Juan, O, Leon, C, Lianes, P, Lopez-Rios, F, Molins, L, Planchuelo, MA, Cobo, M, Paz-Ares, L, Trigo, JM, and de Castro, J

Subjects
Quality of life, EGFR, Smoking, Gender, Lung cancer
Abstract

Lung cancer is the most common cancer globally and has the highest mortality. Although this disease is not associated with a particular gender, its incidence is rising among women, who are diagnosed at an increasingly younger age compared with men. One of the main reasons for this rise is women taking up smoking. However, many non-smoking women also develop this disease. Other risk factors implicated in the differential development of lung cancer in women are genetic predisposition, tumour histology and molecular profile. Proportionally more women than men with lung cancer have a mutation in the EGFR gene. This consensus statement reviews the available evidence about the epidemiological, biological, diagnostic, therapeutic, social and psychological aspects of lung cancer in women.

Published
2017

24. 81P Predictive molecular parameters of pneumonitis development in stage IIIa NSCLC patients treated with neo-adjuvant chemo-immunotherapy from NADIM clinical trial

Author

Sierra-Rodero, B., Garitaonaindia, Y., Martinez-Cutillas, M., Nadal, E., Insa, A., Campelo, M.R. Garcia, Rubio, J. Casal, Gomez, M. Domine, Tarruella, M. Majem, Abreu, D. Rodriguez, Martinez-Marti, A., De Castro Carpeno, J., del Barco, E., Viñolas, N., Aranda, I.C. Barneto, Sureda, B. Massuti, Casarrubios, M., Laza-Briviesca, R., Cruz-Bermudez, A., and Provencio, M.

Published
2021
Full Text
View/download PDF

25. P60.11 TCR Repertoire Predicts Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemoimmunotherapy from NADIM Trial

Author

Casarrubios, M., Nadal, E., Cruz-Bermudez, A., Insa, A., Briviesca, R. Laza, Campelo, M.R. Garcia, Sierra-Rodero, B., Casal, J., Dómine, M., Massuti, B., Tarruella, M. Majem, Rodríguez-Abreu, D., Martinez-Marti, A., De Castro Campeño, J., Dols, M. Cobo, Vivanco, G. López, Del Barco, E., Caro, R. Bernabé, Viñolas, N., Barneto, I., Viteri, S., Jove, M., Franco, F., and Provencio, M.

Published
2021
Full Text
View/download PDF

26. P60.07 TMB and Selected Mutations in Resectable Stage IIIA NSCLC Patients Receiving Neo-Adjuvant Chemo-Immunotherapy from NADIM Trial

Author

Cruz-Bermudez, A., Casarrubios, M., Briviesca, R. Laza, Nadal, E., Insa, A., Mosquera, J., Huidobro, G., Gómez, M. Dómine, Massuti, B., Tarruella, M. Majem, Rodríguez-Abreu, D., Martinez-Marti, A., De Castro Campeño, J., Dols, M. Cobo, Vivanco, G. López, Del Barco, E., Caro, R. Bernabé, Viñolas, N., Barneto, I., Viteri, S., Jove, M., Romero, A., Franco, F., and Provencio, M.

Published
2021
Full Text
View/download PDF

30. FP12.09 Molecular Insight into NADIM Clinical Trial: Potential Immune Biomarkers of Pathological Response for NSCLC Patients.

Author

Laza Briviesca, R., Nadal, E., Casarrubios, M., Insa, A., Sierra-Rodero, B., Garcia Campelo, M.R., Huidobro, G., Dómine Gómez, M., Massuti, B., Majem, M., Rodríguez-Abreu, D., Martinez-Marti, A., De Castro Campeño, J., Cobo Dols, M., López Vivanco, G., Del Barco, E., Bernabé Caro, R., Viñolas, N., Barneto, I., Viteri, S., Cruz-Bermudez, A., and Provencio, M.

Published
2021
Full Text
View/download PDF

33. OA01.05 Phase II Study of Neo-Adjuvant Chemo/Immunotherapy for Resectable Stages IIIA Non-Small Cell Lung Cancer- Nadim Study-SLCG

Author

Provencio, M., primary, Nadal, E., additional, Insa, A., additional, García Campelo, R., additional, Huidobro, G., additional, Domine, M., additional, Majem, M., additional, Rodríguez-Abreu, D., additional, Calvo, V., additional, Martinez-Marti, A., additional, De Castro, J., additional, Cobo Dols, M., additional, Lopez-Vivanco, G., additional, Del Barco, E., additional, Bernabé, R., additional, Vinolas, N., additional, Barneto, I., additional, and Massuti, B., additional

Published
2018
Full Text
View/download PDF

34. P3.04-13 PD-L1-Gene Expression by nCounter Correlates with PD-L1 Protein Expression in Advanced Non-Small Cell Lung Cancer (NSCLC)

Author

Cabrera, C., primary, Aguado, C., additional, Teixidó, C., additional, Pare, L., additional, Castellvi, J., additional, López, L., additional, Marin, E., additional, Bernal, X., additional, Martinez, D., additional, Giménez-Capitán, A., additional, Vinolas, N., additional, Yeste, Z., additional, Baixeras, N., additional, Roman, R., additional, Molina-Vila, M., additional, and Reguart, N., additional

Published
2018
Full Text
View/download PDF

35. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Author

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, Van Den Weyngaert D, Kaendler S, Krauseneck P, Vinolas N, Villa S, Wurm RE, Maillot MHB, Spagnolli F, Kantor G, Malhaire JP, Renard L, De Witte O, Scandolaro L, Vecht CJ, Maingon P, Lutterbach J, Kobierska A, Bolla M, Souchon R, Mitine C, Tzuk-Shina T, Kuten A, Haferkamp G, de Greve J, Priou F, Menten J, Rutten I, Clavere P, Malmstrom A, Jancar B, Newlands E, Pigott K, Twijnstra A, Chinot O, Reni M, Boiardi A, Fabbro M, Campone M, Bozzino J, Frenay M, Gijtenbeek J, Delattre JY, De Paula U, Hanzen C, Pavanato G, Schraub S, Pfeffer R, Soffietti R, Kortmann RD, Taphoorn M, Torrecilla JL, Grisold W, Huget P, Forsyth P, Fulton D, Kirby S, Wong R, Fenton D, Cairncross G, Whitlock P, Burdette-Radoux S, Gertler S, Saunders S, Laing K, Siddiqui J, Martin LA, Gulavita S, Perry J, Mason W, Thiessen B, Pai H, Alam ZY, Eisenstat D, Mingrone W, Hofer S, Pesce G, Dietrich PY, Thum P, Baumert B, Ryan G, Stupp, R, Mason, Wp, van den Bent, Mj, Weller, M, Fisher, B, Taphoorn, Mjb, Belanger, K, Brandes, Aa, Marosi, C, Bogdahn, U, Curschmann, J, Janzer, Rc, Ludwin, Sk, Gorlia, T, Allgeier, A, Lacombe, D, Cairncross, Jg, Eisenhauer, E, Mirimanoff, Ro, Van Den Weyngaert, D, Kaendler, S, Krauseneck, P, Vinolas, N, Villa, S, Wurm, Re, Maillot, Mhb, Spagnolli, F, Kantor, G, Malhaire, Jp, Renard, L, De Witte, O, Scandolaro, L, Vecht, Cj, Maingon, P, Lutterbach, J, Kobierska, A, Bolla, M, Souchon, R, Mitine, C, Tzuk-Shina, T, Kuten, A, Haferkamp, G, de Greve, J, Priou, F, Menten, J, Rutten, I, Clavere, P, Malmstrom, A, Jancar, B, Newlands, E, Pigott, K, Twijnstra, A, Chinot, O, Reni, M, Boiardi, A, Fabbro, M, Campone, M, Bozzino, J, Frenay, M, Gijtenbeek, J, Delattre, Jy, De Paula, U, Hanzen, C, Pavanato, G, Schraub, S, Pfeffer, R, Soffietti, R, Kortmann, Rd, Taphoorn, M, Torrecilla, Jl, Grisold, W, Huget, P, Forsyth, P, Fulton, D, Kirby, S, Wong, R, Fenton, D, Cairncross, G, Whitlock, P, Burdette-Radoux, S, Gertler, S, Saunders, S, Laing, K, Siddiqui, J, Martin, La, Gulavita, S, Perry, J, Mason, W, Thiessen, B, Pai, H, Alam, Zy, Eisenstat, D, Mingrone, W, Hofer, S, Pesce, G, Dietrich, Py, Thum, P, Baumert, B, Ryan, G, Neurology, and Plastic and Reconstructive Surgery and Hand Surgery

Subjects
Adult, Male, medicine.medical_specialty, medicine.medical_treatment, Adrenal Cortex Hormones, Adrenal Cortex Hormones/therapeutic use Adult Aged Antineoplastic Agents, Alkylating/adverse effects/*therapeutic use Brain Neoplasms/*drug therapy/mortality/*radiotherapy Chemotherapy, Adjuvant Dacarbazine/adverse effects/*analogs & derivatives/*therapeutic use Disease Progression Female Glioblastoma/*drug therapy/mortality/*radiotherapy Humans Male Middle Aged Proportional Hazards Models Radiotherapy, Computer-Assisted/adverse effects Survival Analysis, medicine, Temozolomide, Humans, Survival rate, Pseudoprogression, Antineoplastic Agents, Alkylating, Aged, Proportional Hazards Models, business.industry, Brain Neoplasms, Hazard ratio, General Medicine, Middle Aged, Debulking, medicine.disease, Survival Analysis, Radiotherapy, Computer-Assisted, Surgery, Radiation therapy, Dacarbazine, Chemotherapy, Adjuvant, Concomitant, Disease Progression, Female, business, Glioblastoma, medicine.drug, Anaplastic astrocytoma
Abstract

BACKGROUND: Glioblastoma, the most common primary brain tumor in adults, is usually rapidly fatal. The current standard of care for newly diagnosed glioblastoma is surgical resection to the extent feasible, followed by adjuvant radiotherapy. In this trial we compared radiotherapy alone with radiotherapy plus temozolomide, given concomitantly with and after radiotherapy, in terms of efficacy and safety. METHODS: Patients with newly diagnosed, histologically confirmed glioblastoma were randomly assigned to receive radiotherapy alone (fractionated focal irradiation in daily fractions of 2 Gy given 5 days per week for 6 weeks, for a total of 60 Gy) or radiotherapy plus continuous daily temozolomide (75 mg per square meter of body-surface area per day, 7 days per week from the first to the last day of radiotherapy), followed by six cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28-day cycle). The primary end point was overall survival. RESULTS: A total of 573 patients from 85 centers underwent randomization. The median age was 56 years, and 84 percent of patients had undergone debulking surgery. At a median follow-up of 28 months, the median survival was 14.6 months with radiotherapy plus temozolomide and 12.1 months with radiotherapy alone. The unadjusted hazard ratio for death in the radiotherapy-plus-temozolomide group was 0.63 (95 percent confidence interval, 0.52 to 0.75; P

Published
2005

36. Automated nCounter-based assay for identifying clinically relevant ALK, ROS1 and RET rearrangements in advanced non-small cell lung cancer (NSCLC)

Author

Reguart, N., Pare, L., Gimenez-Capitan, A., Teixido, C., Galvan, P., Viteri, S., Rodriguez, S., Peg, V., Aldeguer, E., Ovalle, E., Vinolas, N., Merkelbach-Bruse, S., Lopez-Rios, F., Rosell, R., Molina-Vila, M. A., Prat, A., Reguart, N., Pare, L., Gimenez-Capitan, A., Teixido, C., Galvan, P., Viteri, S., Rodriguez, S., Peg, V., Aldeguer, E., Ovalle, E., Vinolas, N., Merkelbach-Bruse, S., Lopez-Rios, F., Rosell, R., Molina-Vila, M. A., and Prat, A.

Published
2016

40. 1241P - Immune cell biomarkers on neo-adjuvant chemo-immunotherapy treatment for resectable stage IIIA NSCLC patients

Author

Laza-Briviesca, R., Cruz-Bermudez, A., Casarrubios, M., Nadal, E., Molla, M A Insa, García-Campelo, M.-R., Huidobro, G., Gomez, M Domine, Tarruella, M Majem, Abreu, D Rodriguez, Martinez-Marti, A., De Carpeno, JCastro, Dols, M Cobo, Vivanco, G López, del Barco Morillo, E., Bernabé, R., Viñolas, N., Aranda, I C Barneto, Sureda, B Massuti, and Provencio, M.

Published
2019
Full Text
View/download PDF

45. P2.04-10 Biomarkers of Pathological Response on Neo-Adjuvant Chemo-Immunotherapy Treatment for Resectable Stage IIIA NSCLC Patients

Author

Laza-Briviesca, R., Cruz-Bermudez, A., Casarrubios, M., Nadal, E., Insa, A., Campelo, R. Garcia, De Dios Alvarez, N., Domine, M., Majem, M., Rodriguez-Abreu, D., De Juan, V. Calvo, Martinez-Marti, A., De Castro Carpeno, J., Cobo, M., López-Vivanco, G., Del Barco, E., Bernabe, R., Viñolas, N., Barneto, I., Viteri, S., Massuti, B., and Provencio, M.

Published
2019
Full Text
View/download PDF

47. P1.01-72 A Phase II Study of Selective AXL Inhibitor Bemcentinib and Pembrolizumab in Patients with NSCLC Refractory to Anti-PD(L)1

Author

Krebs, M., Brunsvig, P., Helland, Å., Viñolas, N., Aix, S., Carcereny, E., Gomez, M. Dómine, Perez, J.M. Trigo, Arriola, E., Campelo, R. Garcia, Spicer, J., Thompson, J., Granados, A.L. Ortega, Holt, R., Smethurst, D., Lorens, J., Shoaib, M., Siddiqui, A., Schoelermann, J., Lorens, K., Schmidt, E., Chisamore, M.J., and Felip, E.

Published
2019
Full Text
View/download PDF

50. MA03.06 Efficacy Results of Selective AXL Inhibitor Bemcentinib with Pembrolizumab Following Chemotherapy in Patients with NSCLC

Author

Felip, E., Brunsvig, P., Helland, Å., Viñolas, N., Aix, S., Carcereny, E., Gomez, M. Dómine, Perez, J.M. Trigo, Arriola, E., Campelo, R. Garcia, Spicer, J., Thompson, J., Granados, A.L. Ortega, Holt, R., Smethurst, D., Lorens, J., Shoaib, M., Siddiqui, A., Schoelermann, J., Lorens, K., Schmidt, E., Chisamore, M.J., and Krebs, M.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results